Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Global single arm, open-label Phase 1/2 trial of TSHA-118 for the treatment of CLN1 disease

Next Previous
Trial Profile

Global single arm, open-label Phase 1/2 trial of TSHA-118 for the treatment of CLN1 disease

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABO 202 (Primary)
  • Indications Neuronal ceroid lipofuscinosis
  • Focus Therapeutic Use

Most Recent Events

  • 22 Dec 2021 New trial record
  • 16 Dec 2021 According to a Taysha Gene Therapies media release, preliminary clinical safety and PPT1 enzyme activity data in the serum and CSF are expected in the first half of 2022.
  • 16 Dec 2021 According to a Taysha Gene Therapies media release, clinical trial application has been approved by Health Canada in November 2021 and Queen's University in Ontario Canada has been selected as the initial clinical site under the direction of principal investigator Jagdeep S. Walia.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top